Holding 200k plus in a pre-revenue diagnostics company is...

Holding 200k plus in a pre-revenue diagnostics company is inherently a risky position. Lets be honest that’s the nature of this end of the market, biotechs/medtechs are classic asymmetric plays. Most outcomes cluster near zero for years and years while a few eventually go exponential, that is the risk profile we all have accepted. I have seen the share register recently, there are many, many people with large bags so I would not make that assumption. Your desire for what you believe is best, be it a pivot to the east coast, faster US entry or immediate sales traction totally overlooks the operational and regulatory realities of running a company like this. Strategic sequencing, like launching in WA or NT likely reflects where implementation is most feasible not just where the biggest pops are. In diagnostics early deployment depends on factors like state health department engagement, hospital partnerships, procurement processes the ability to monitor and support early adoption etc etc. WA for example, has a more unified public health system compared to the fragmented structures across NSW or VIC. That makes it a more controlled environment to deploy and refine. It’s not always about pop size, it’s about execution feasibility.

You say Richard is fixated on getting filthy rich, yet simultaneously accuse him of not doing enough to grow the company. Bit of a contradiction, wealth in a company like this only comes from value creation. You can’t have it both ways. Either he is trying to build something worth real money, or he is not. If the goal was just personal gain, the fastest path would be short term hype not slow methodical execution. Slow growth does not equal a lack of progress especially in a sector where everything takes time.

I agree, anyone putting serious capital into early stage pre-rev diagnostics needs to think in nuance, not impatience.
Emotion only creeps in when you’re overinvested beyond your comfort levels. And if that’s the case, the issue isn’t the company it’s position sizing.
I added via the SPP, noting options expiring might weigh on price in the short term capping growth too. Unbothered unless fundamentals change, which they haven't.
Also just a friendly note, not all of us with large portfolios are guys.